Cellebrite cuts forecasts, and the stock plummets in trading on Wall Street
The digital intelligence company reported a 16% growth in revenue for the second quarter, but failed to beat market expectations and lowered its forecasts for the future. At the same time, it announced a change of CEOs. Meanwhile, on Wall Street, the 'buy' recommendation for the stock is being maintained.
The heavy pressure on Cellebrite stock reached a peak with the publication of its financial results for the second quarter of 2026. Although the digital intelligence company from Petah Tikva recorded a 16% increase in revenue to $131.1 million and growth in Annual Recurring Revenue (ARR) to $507.8 million, the financial figures were significantly lower than market expectations and the management's previous guidance. The stock is plummeting sharply at the opening of trading.
The company reduced the annual ARR forecast to $550-560 million and cut the revenue forecast to $555-561 million. The company explained the miss by the lengthening of sales cycles with law enforcement and security agencies worldwide, alongside a slower-than-expected adoption rate of its Inseyets platform upgrades.
Simultaneously with the publication of the reports, the company announced the replacement of CEO Thomas Hogan. He will be succeeded by Shivan Ramji, who joined the company only three months earlier as President of Products. According to the company's announcement, this is a "planned transition" aimed at placing a world-class technology and product person at the head of the organization. Hogan noted:
"The next chapter of Cellebrite requires a world-class product and technology leader, and Shivan is exactly that leader."
Incoming CEO Shivan Ramji addressed the results:
"We reached ARR results lower than expectations following longer sales cycles. Resetting expectations now is the most responsible step that provides a more correct basis for execution going forward."
Ramji noted that operational discipline allowed the company to raise the annual adjusted EBITDA target to $153-159 million.
Investor view: risk or opportunity?
Wall Street analysts are maintaining cautious optimism for now regarding what is to come. According to analyst consensus data, the stock holds a "Moderate Buy" rating based on 5 buy recommendations and one hold recommendation, with an average target price of $21.80 — reflecting an 'upside' potential of about 43% from its current price ($15.25).
Bottom line, analysts and analysis networks like The Motley Fool note that Cellebrite's position as one of the world's leading digital forensics platforms, alongside receiving prestigious federal security certification and the implementation of advanced AI tools (Genesis), give the company a strong competitive advantage. Now, the burden of proof shifts to the shoulders of the new CEO.
